Bioventus Q4 earnings beat expectations, stock surges 7.6% pre-market

LootboxPhobia · 2026-03-05T20:59:57+00:00

Medical device manufacturer Bioventus announced Q4 results, with an adjusted EPS of $0.24, beating expectations. Net sales reached $157.9 million, also surpassing market expectations. The stock price rose 7.58% in pre-market trading. The company expects net sales for fiscal year 2026 to reach $600-610 million.

LootboxPhobia

2026-03-05 20:59:57

Abstract generation in progress

Investing.com – Medical device manufacturer Bioventus (NASDAQ:BVS) stock rose 7.58% pre-market on Thursday to $9.11, after the company reported Q4 earnings that exceeded Wall Street expectations.

The company posted adjusted earnings of $0.24 per share for the quarter, surpassing the analyst consensus of $0.22, according to LSEG data. Net sales reached $157.9 million, above the market expectation of $154.9 million.

Sales of pain management products increased 15.1% to $79.7 million, driven mainly by strong demand for the company’s knee osteoarthritis injections. Surgical solutions sales grew 3.4% to $55.5 million, benefiting from increased demand for bone graft products in the U.S. market.

For fiscal year 2026, Bioventus expects net sales between $600 million and $610 million. Analysts previously forecast annual sales of $604.2 million.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes